Skip to main content
Clinical Trials/NCT04048889
NCT04048889
Unknown
Not Applicable

Addition of Popliteal Plexus Block to Continuous Femoral Nerve Block for Total Knee Arthroplasty

University Hospital, Geneva1 site in 1 country66 target enrollmentJuly 22, 2019

Overview

Phase
Not Applicable
Intervention
Ropivacaine 0.5% Injectable Solution
Conditions
Pain, Postoperative
Sponsor
University Hospital, Geneva
Enrollment
66
Locations
1
Primary Endpoint
Total iv morphine consumption (mg)
Last Updated
6 years ago

Overview

Brief Summary

The popliteal plexus block has been described as an alternative analgesic postoperative pain treatment for total knee arthroplasty. It consists of injecting local anaeshetics inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor magnus muscle, in order to anesthetize the popliteal plexus. However, the analgesic efficacy has never been demonstrated in a randomized controlled trial. Therefore the objective of this study is to investigate the analgesic benefit of this block combined with a continuous femoral nerve block, on patients scheduled for total knee athroplasty.

Detailed Description

Patients scheduled to undergo total knee arthroplasty under general anesthesia will be randomly allocated to two groups: continuous femoral nerve block alone or continuous femoral nerve block with addition of a popliteal plexus block. The continuous femoral nerve block will be performed by the anesthesiologist with 15 mLs of ropivacaine 0.5%, under ultrasound guidance before the beginning of the general anesthesia. The popliteal plexus block will be done by the anesthesiology, under ultrasound guidance, before the beginning of the surgery, under general anesthesia. Postoperative analgesia will include acetaminophen (4 x 1000 mg), ibuprofen (3 x 400 mg) and a continuous infusion of Ropivacaine 0.2%.

Registry
clinicaltrials.gov
Start Date
July 22, 2019
End Date
July 1, 2022
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kevin Stebler

Principal Investigator

University Hospital, Geneva

Eligibility Criteria

Inclusion Criteria

  • Patients scheduled for total knee athroplasty under general anesthesia

Exclusion Criteria

  • Kidney disease with GFR \< 50 ml/mn
  • Daily opioid consumption \> 1 month
  • Allergy to local anesthetics
  • Neurological problems of the lower extremity
  • other contraindications to peripheral nerve blocks

Arms & Interventions

Popliteal plexus block and continuous femoral nerve block

Intervention: Ropivacaine 0.5% Injectable Solution

continuous femoral nerve block

Intervention: Ropivacaine 0.5% Injectable Solution

Outcomes

Primary Outcomes

Total iv morphine consumption (mg)

Time Frame: 12 postoperative hours

Secondary Outcomes

  • Average and maximum pain scores (Numeric rating scale 0-10)(12, 24 and 48 postoperative hours)
  • Popliteal plexus block duration of action (hours)(up to 48 postoperative hours)
  • Knee pain localization (anterior, internal, posterior, lateral, medial)(2, 12, 24 and 48 postoperative hours)
  • Popliteal plexus block procedure time (minutes)(When performing the popliteal plexus block)
  • Total iv morphine consumption (mg)(24 and 48 postoperative hours)
  • Plantarflexion and dorsiflexion ankle strength (Newtons)(2 and 24 postoperative hours)
  • Sciatic extension of popliteal plexus block(2 and 24 postoperative hours)

Study Sites (1)

Loading locations...

Similar Trials